Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 4, 2, 1, 9, 2 and 1 respectively.

Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Nausea and Vomiting - Overview
Chemotherapy Induced Nausea and Vomiting - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
Acacia Pharma Ltd
Aphios Corp
Astellas Pharma Inc
Camurus AB
Daewoong Pharmaceutical Co Ltd
Heron Therapeutics Inc
INSYS Therapeutics Inc
Kyowa Hakko Kirin Co Ltd
MannKind Corp
Medlab Clinical Ltd
Nemus Bioscience Inc
RedHill Biopharma Ltd
Serina Therapeutics Inc
SoluBest Ltd
Suda Ltd
Tesaro Inc
Therapix Biosciences Ltd
Chemotherapy Induced Nausea and Vomiting - Drug Profiles
(netupitant + palonosetron hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(palonosetron hydrochloride + Pro-netupitant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APD-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cannabis CINV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FK-886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosnetupitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
granisetron hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPI-1504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPI-1505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palonosetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rolapitant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SER-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Nausea and Vomiting - Dormant Projects
Chemotherapy Induced Nausea and Vomiting - Discontinued Products
Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
Featured News & Press Releases
Feb 27, 2017: TESARO Receives Positive CHMP Opinion for VARUBY
Feb 23, 2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant)
Jan 12, 2017: Heron Announces Submission of CINVANTI NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA
Oct 27, 2016: Mundipharma Launches Step-change Cancer Care Medicine Akynzeo in Singapore
Sep 06, 2016: TESARO to present data on Rolapitant at the 2016 European Society for Medical Oncology Annual Meeting
Jun 23, 2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing
May 18, 2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting
Apr 12, 2016: Suda Granted Canadian Patent For Sud-002 Oral Spray To Treat Nausea & Vomiting
Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
Feb 01, 2016: Biologics Announces New Oncology Partnership
Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics Inc, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics Inc, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Medlab Clinical Ltd, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience Inc, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Serina Therapeutics Inc, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro Inc, H1 2017
Chemotherapy Induced Nausea and Vomiting - Pipeline by Therapix Biosciences Ltd, H1 2017
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2017
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2017 (Contd..1), H1 2017
Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H1 2017